Using a virus to deliver HIV inhibitors for treatment
AAV-delivered HIV inhibitors for SHIV therapy
['FUNDING_R01'] · EMORY UNIVERSITY · NIH-11109480
This study is looking at a new way to help people with HIV by using a special virus to deliver antibodies that can fight the virus, aiming to keep it under control for a long time with just one treatment.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | EMORY UNIVERSITY (nih funded) |
| Locations | 1 site (ATLANTA, UNITED STATES) |
| Trial ID | NIH-11109480 on ClinicalTrials.gov |
What this research studies
This research investigates the use of adeno-associated virus (AAV) vectors to deliver broadly neutralizing antibodies (bNAbs) that can help suppress HIV-1 in patients. By using a single dose of these AAV vectors, the goal is to achieve long-term expression of bNAbs, which could maintain viral suppression and reduce the viral reservoir in the body. The study also explores strategies to overcome the immune response that can limit the effectiveness of these treatments, potentially leading to improved outcomes for individuals living with HIV.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals living with HIV who have not achieved viral suppression with current antiretroviral therapies.
Not a fit: Patients who are not living with HIV or those who have a complete viral suppression with existing therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a more effective long-term treatment option for patients living with HIV, reducing the need for daily antiretroviral therapy.
How similar studies have performed: Previous studies have shown promise in using similar approaches with bNAbs, indicating potential for success in this novel application.
Where this research is happening
ATLANTA, UNITED STATES
- EMORY UNIVERSITY — ATLANTA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: GARDNER, MATTHEW RYAN — EMORY UNIVERSITY
- Study coordinator: GARDNER, MATTHEW RYAN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Acquired Immune Deficiency Syndrome Virus, Acquired Immunodeficiency Syndrome Virus